Menu Search
Equities

Incyte Corp

INCY:NSQ

Incyte Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)70.39
  • Today's Change-0.66 / -0.93%
  • Shares traded2.15m
  • 1 Year change+32.24%
  • Beta0.6860
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy9
Outperform3
Hold13
Sell1
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Incyte Corp have a median target of 75.06, with a high estimate of 97.00 and a low estimate of 52.00. The median estimate represents a 6.63% increase from the last price of 70.39.
High37.8%97.00
Med6.6%75.06
Low-26.1%52.00

Earnings history & estimates in USD

On Oct 29, 2024, Incyte Corp reported 3rd quarter 2024 earnings of 1.07 per share. This result was in line with the consensus of the 15 analysts following the company and under-performed last year's 3rd quarter results by 2.73%.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate-21.63%
Incyte Corp reported annual 2023 earnings of 3.52 per share on Feb 13, 2024.
Average growth rate+13.67%
More ▼

Revenue history & estimates in USD

Incyte Corporation had 3rd quarter 2024 revenues of 1.14bn. This bettered the 1.08bn consensus of the 18 analysts covering the company. This was 40.71% above the prior year's 3rd quarter results.
Average growth rate+6.17%
Incyte Corporation had revenues for the full year 2023 of 3.70bn. This was 8.87% above the prior year's results.
Average growth rate+14.51%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.